Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $141.10 | Total: $705.50 |
| 1 | 10 | $119.52 | Total: $1,195.20 |
| 1 | 25 | $101.26 | Total: $2,531.50 |
| 1 | 50 | $86.32 | Total: $4,316.00 |
| 1 | 100 | $74.70 | Total: $7,470.00 |
Overview
Isomer-Turosteride (Isomer-Turosteride(Isomer-137099-09-3)) is a novel 5 alpha-reductase inhibitor.The antiprostatic effect of Isomer-Turosteride in adult rats is associated with the inhibition of the conversion of T to DHT.Isomer-Turosteride induces a decrease in prostate DHT independent of a secondary increase in T. Isomer-Turosteride has anticancer activity and inhibits the growth of tumor cells. Turosteride has anticancer activity and inhibits the growth of tumor cells.Translated with www.DeepL.comTranslator (free version)
Chemical Properties
| Molecular Formula | C27H45N3O3 |
| Molecular Weight | 459.67 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | C[C@@]12[C@](CC[C@@H]2C(N(C(C)C)C(NC(C)C)=O)=O)([H])[C@@]3([H])[C@@](CC1)([H])[C@@]4([C@](N(C(CC4)=O)C)([H])CC3)C |
Storage and Handling
0C Short Term, -20C Long Term
References
Hudak SJ, et al. Role of 5 alpha-reductase inhibitors in the management of prostate cancer. Clin Interv Aging. 2006;1[4] 425-431.